Massachusetts Financial Services Co. MA Sells 12,433 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Massachusetts Financial Services Co. MA lowered its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 1.9% during the 2nd quarter, Holdings Channel reports. The firm owned 649,365 shares of the specialty pharmaceutical company’s stock after selling 12,433 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Collegium Pharmaceutical were worth $20,910,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in COLL. Vanguard Group Inc. lifted its position in shares of Collegium Pharmaceutical by 0.8% in the first quarter. Vanguard Group Inc. now owns 2,330,728 shares of the specialty pharmaceutical company’s stock worth $90,479,000 after buying an additional 17,942 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of Collegium Pharmaceutical by 8.2% during the 2nd quarter. Principal Financial Group Inc. now owns 1,680,860 shares of the specialty pharmaceutical company’s stock valued at $54,124,000 after acquiring an additional 128,003 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Collegium Pharmaceutical by 2.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,039,218 shares of the specialty pharmaceutical company’s stock valued at $31,987,000 after purchasing an additional 29,529 shares in the last quarter. Emerald Mutual Fund Advisers Trust increased its position in Collegium Pharmaceutical by 3.8% in the second quarter. Emerald Mutual Fund Advisers Trust now owns 530,456 shares of the specialty pharmaceutical company’s stock worth $17,081,000 after purchasing an additional 19,255 shares during the last quarter. Finally, LSV Asset Management raised its stake in Collegium Pharmaceutical by 188.7% during the first quarter. LSV Asset Management now owns 380,551 shares of the specialty pharmaceutical company’s stock valued at $14,773,000 after purchasing an additional 248,751 shares in the last quarter.

Collegium Pharmaceutical Stock Up 0.4 %

Shares of NASDAQ COLL opened at $39.07 on Friday. The company has a market cap of $1.28 billion, a P/E ratio of 16.28 and a beta of 0.94. The firm has a 50-day simple moving average of $36.09 and a two-hundred day simple moving average of $35.47. Collegium Pharmaceutical, Inc. has a 1 year low of $20.95 and a 1 year high of $40.95. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.11 and a quick ratio of 1.04.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.22. The firm had revenue of $145.28 million during the quarter, compared to analyst estimates of $143.94 million. Collegium Pharmaceutical had a return on equity of 107.62% and a net margin of 17.32%. Collegium Pharmaceutical’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same period last year, the company earned $1.13 EPS. Research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.82 earnings per share for the current year.

Insider Activity

In related news, EVP Shirley R. Kuhlmann sold 19,248 shares of the firm’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $38.30, for a total value of $737,198.40. Following the transaction, the executive vice president now owns 120,161 shares of the company’s stock, valued at approximately $4,602,166.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, EVP Thomas B. Smith sold 9,593 shares of the stock in a transaction on Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the transaction, the executive vice president now owns 53,816 shares of the company’s stock, valued at approximately $1,970,741.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of the firm’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total value of $737,198.40. Following the transaction, the executive vice president now owns 120,161 shares in the company, valued at approximately $4,602,166.30. The disclosure for this sale can be found here. Insiders own 3.98% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on COLL shares. Needham & Company LLC reissued a “hold” rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Jefferies Financial Group raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $41.00 to $44.00 in a research note on Friday, June 7th. StockNews.com lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 31st. HC Wainwright boosted their target price on Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, September 5th. Finally, Truist Financial raised their price target on Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $42.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.